Multiscale Analysis and Validation of Effective Drug Combinations Targeting Driver KRAS Mutations in Non-Small Cell Lung Cancer
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24020997 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Liana Bruggemann und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Informatics, University at Buffalo, Buffalo, NY 14260, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NLM NIH HHS, NIH HHS.
Abstract (Originalsprache)
Pharmacogenomics is a rapidly growing field with the goal of providing personalized care to every patient. Previously, we developed the Computational Analysis of Novel Drug Opportunities (CANDO) platform for multiscale therapeutic discovery to screen optimal compounds for any indication/disease by performing analytics on their interactions using large protein libraries. We implemented a comprehensive precision medicine drug discovery pipeline within the CANDO platform to determine which drugs are most likely to be effective against mutant phenotypes of non-small cell lung cancer (NSCLC) based on the supposition that drugs with similar interaction profiles (or signatures) will have similar behavior and therefore show synergistic effects. CANDO predicted that osimertinib, an EGFR inhibitor, is most likely to synergize with four KRAS inhibitors.Validation studies with cellular toxicity assays confirmed that osimertinib in combination with ARS-1620, a KRAS G12C inhibitor, and BAY-293, a pan-KRAS inhibitor, showed a synergistic effect on decreasing cellular proliferation by acting on mutant KRAS. Gene expression studies revealed that MAPK expression is strongly correlated with decreased cellular proliferation following treatment with KRAS inhibitor BAY-293, but not treatment with ARS-1620 or osimertinib. These results indicate that our precision medicine pipeline may be used to identify compounds capable of synergizing with inhibitors of KRAS G12C, and to assess their likelihood of becoming drugs by understanding their behavior at the proteomic/interactomic scales.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Informatics, University at Buffalo, Buffalo, NY 14260, USA.
- Department of Medicine, University at Buffalo, Buffalo, NY 14260, USA.
- Roswell Park Cancer Institute, Buffalo, NY 14203, USA.
ORCID-Profile: Zackary Falls, William Mangione, Stanley A Schwartz, Ravikumar Aalinkeel, Ram Samudrala
Förderung
- NCATS NIH HHS
- NLM NIH HHS
- NIH HHS
- NIDA NIH HHS
- National Institutes of Health (NIH) Director’s Pioneer Award
- NIH Clinical and Translational Sciences (NCATS) Award
- NIH National Library of Medicine (NLM) T15 Award
- NIH NLM R25 Award
Zitieren
APA
Bruggemann, L., Falls, Z., Mangione, W., Schwartz, S. A., Battaglia, S., Aalinkeel, R., Mahajan, S. D., & Samudrala, R. (2023). Multiscale Analysis and Validation of Effective Drug Combinations Targeting Driver KRAS Mutations in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24020997
Vancouver
Bruggemann L, Falls Z, Mangione W, Schwartz SA, Battaglia S, Aalinkeel R, et al. Multiscale Analysis and Validation of Effective Drug Combinations Targeting Driver KRAS Mutations in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24020997
BibTeX
@article{Bruggemann2023,
author = {Bruggemann, Liana and Falls, Zackary and Mangione, William and Schwartz, Stanley A and Battaglia, Sebastiano and Aalinkeel, Ravikumar and Mahajan, Supriya D and Samudrala, Ram},
title = {Multiscale Analysis and Validation of Effective Drug Combinations Targeting Driver KRAS Mutations in Non-Small Cell Lung Cancer},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24020997}
}
EUVIMED